Interleukin-4 Gene Polymorphisms in Romanian Patients with Inflammatory Bowel Diseases: Association with Disease Risk and Clinical Features
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population and Ethics
2.2. SNP Selection and Genoty**
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Nemeth, Z.H.; Bogdanovski, D.A.; Barratt-Stopper, P.; Paglinco, S.R.; Antonioli, L.; Rolandelli, R.H. Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles. Cureus 2017, 9, e1177. [Google Scholar] [CrossRef]
- Vavricka, S.R.; Schoepfer, A.; Scharl, M.; Lakatos, P.L.; Navarini, A.; Rogler, G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2015, 21, 1982–1992. [Google Scholar] [CrossRef]
- Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017, 390, 2769–2778. [Google Scholar] [CrossRef]
- Sultan, S.; El-Mowafy, M.; Elgaml, A.; Ahmed, T.A.E.; Hassan, H.; Mottawea, W. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. Front. Physiol. 2021, 12, 715506. [Google Scholar] [CrossRef]
- Shih, D.Q.; Targan, S.R. Immunopathogenesis of inflammatory bowel disease. World J. Gastroenterol. 2008, 14, 390–400. [Google Scholar] [CrossRef]
- Vetuschi, A.; Pompili, S.; Gaudio, E.; Latella, G.; Sferra, R. PPAR-γ with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 8839–8848. [Google Scholar] [CrossRef]
- Monteleone, G.; Biancone, L.; Wedel, S.; Pallone, F. IL-4 hyporesponsiveness of Crohn’s disease mucosal T lymphocytes: A response of polarised Th1 cells? Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 2000, 32, 495–497. [Google Scholar] [CrossRef]
- Sher, A.; Kelsall, B.L. The Colon as a Major Site of Immunoregulation by CD4+ T Cell Subsets in the Steady State. J. Immunol. Baltim. Md. 1950 2019, 203, 1683–1684. [Google Scholar] [CrossRef]
- Li, J.; Ueno, A.; Fort Gasia, M.; Luider, J.; Wang, T.; Hirota, C.; Jijon, H.B.; Deane, M.; Tom, M.; Chan, R.; et al. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn’s Disease. Inflamm. Bowel Dis. 2016, 22, 1779–1792. [Google Scholar] [CrossRef]
- Imam, T.; Park, S.; Kaplan, M.H.; Olson, M.R. Effector T Helper Cell Subsets in Inflammatory Bowel Diseases. Front. Immunol. 2018, 9, 1212. [Google Scholar] [CrossRef]
- Rockman, M.V.; Hahn, M.W.; Soranzo, N.; Goldstein, D.B.; Wray, G.A. Positive selection on a human-specific transcription factor binding site regulating IL4 expression. Curr. Biol. 2003, 13, 2118–2123. [Google Scholar] [CrossRef]
- Emam, A.A.; Shehab, M.M.M.; Allah, M.A.N.; Elkoumi, M.A.; Abdelaal, N.M.; Mosabah, A.A.A.; Zakaria, M.T.; Sherif, A.M.; Soliman, M.M.; El-Kaffas, R.M.H.; et al. Interleukin-4 −590C/T gene polymorphism in Egyptian children with acute lower respiratory infection: A multicenter study. Pediatr. Pulmonol. 2019, 54, 297–302. [Google Scholar] [CrossRef]
- Alhassan Mohammed, H.; Saboor-Yaraghi, A.A.; Vahedi, H.; Panahi, G.; Hemmasi, G.; Yekaninejad, M.S.; Mirshafiey, A. Immunotherapeutic Effects of β-D Mannuronic Acid on IL-4, GATA3, IL-17 and RORC Gene Expression in the PBMC of Patients with Inflammatory Bowel Diseases. Iran. J. Allergy Asthma Immunol. 2018, 17, 308–317. [Google Scholar] [CrossRef]
- Rückert, Y.; Schindler, U.; Heinig, T.; Nikolaus, S.; Raedler, A.; Schreiber, S. IL-4 Signaling Mechanisms in Inflammatory Bowel Disease Mononuclear Phagocytes. Inflamm. Bowel Dis. 1996, 2, 244–252. [Google Scholar] [CrossRef]
- Luo, X.; Villablanca, E.J. Type 2 immunity in intestinal homeostasis and inflammatory bowel disease. Biochem. Soc. Trans. 2021, 49, 2371–2380. [Google Scholar] [CrossRef]
- McCormick, S.M.; Heller, N.M. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 2015, 75, 38–50. [Google Scholar] [CrossRef]
- Afshan, K.; Sarfraz, K.; Kayani, T.; Firasat, S. IL-4 gene polymorphisms and their association with nematodes infection in Pakistani population. Afr. Health Sci. 2022, 22, 216–228. [Google Scholar] [CrossRef]
- Harb, H.; Chatila, T.A. Mechanisms of Dupilumab. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 2020, 50, 5–14. [Google Scholar] [CrossRef]
- Iwaszko, M.; Biały, S.; Bogunia-Kubik, K. Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis. Cells 2021, 10, 3000. [Google Scholar] [CrossRef]
- Song, X.; Traub, B.; Shi, J.; Kornmann, M. Possible Roles of Interleukin-4 and -13 and Their Receptors in Gastric and Colon Cancer. Int. J. Mol. Sci. 2021, 22, 727. [Google Scholar] [CrossRef]
- Gomollón, F.; Dignass, A.; Annese, V.; Tilg, H.; Van Assche, G.; Lindsay, J.O.; Peyrin-Biroulet, L.; Cullen, G.J.; Daperno, M.; Kucharzik, T.; et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J. Crohns Colitis 2017, 11, 3–25. [Google Scholar] [CrossRef]
- Magro, F.; Gionchetti, P.; Eliakim, R.; Ardizzone, S.; Armuzzi, A.; Barreiro-de Acosta, M.; Burisch, J.; Gecse, K.B.; Hart, A.L.; Hindryckx, P.; et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J. Crohns Colitis 2017, 11, 649–670. [Google Scholar] [CrossRef]
- Satsangi, J.; Silverberg, M.S.; Vermeire, S.; Colombel, J.-F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 2006, 55, 749–753. [Google Scholar] [CrossRef]
- Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am. J. Hum. Genet. 2007, 81, 559–575. [Google Scholar] [CrossRef]
- Strom, T.M. WTF. DeFinetti Program. Available online: http://ihg.gsf.de/cgi-bin/hw/hwa1.pl (accessed on 18 February 2023).
- Moschen, A.R.; Tilg, H.; Raine, T. IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 185–196. [Google Scholar] [CrossRef]
- Gause, W.C.; Wynn, T.A.; Allen, J.E. Type 2 immunity and wound healing: Evolutionary refinement of adaptive immunity by helminths. Nat. Rev. Immunol. 2013, 13, 607–614. [Google Scholar] [CrossRef]
- Bosurgi, L.; Cao, Y.G.; Cabeza-Cabrerizo, M.; Tucci, A.; Hughes, L.D.; Kong, Y.; Weinstein, J.S.; Licona-Limon, P.; Schmid, E.T.; Pelorosso, F.; et al. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. Science 2017, 356, 1072–1076. [Google Scholar] [CrossRef]
- Jayme, T.S.; Leung, G.; Wang, A.; Workentine, M.L.; Rajeev, S.; Shute, A.; Callejas, B.E.; Mancini, N.; Beck, P.L.; Panaccione, R.; et al. Human interleukin-4-treated regulatory macrophages promote epithelial wound healing and reduce colitis in a mouse model. Sci. Adv. 2020, 6, eaba4376. [Google Scholar] [CrossRef]
- Mesko, B.; Poliskal, S.; Szegedi, A.; Szekanecz, Z.; Palatka, K.; Papp, M.; Nagy, L. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med. Genomics 2010, 3, 15. [Google Scholar] [CrossRef]
- Desreumaux, P.; Brandt, E.; Gambiez, L.; Emilie, D.; Geboes, K.; Klein, O.; Ectors, N.; Cortot, A.; Capron, M.; Colombel, J. Distinct cytokine patterns in early and chronic ileal lesions of Crohn’s disease. Gastroenterology 1997, 113, 118–126. [Google Scholar] [CrossRef]
- Rioux, J.D.; Silverberg, M.S.; Daly, M.J.; Steinhart, A.H.; McLeod, R.S.; Griffiths, A.M.; Green, T.; Brettin, T.S.; Stone, V.; Bull, S.B.; et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am. J. Hum. Genet. 2000, 66, 1863–1870. [Google Scholar] [CrossRef] [PubMed]
- Rioux, J.D.; Daly, M.J.; Silverberg, M.S.; Lindblad, K.; Steinhart, H.; Cohen, Z.; Delmonte, T.; Kocher, K.; Miller, K.; Guschwan, S.; et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet. 2001, 29, 223–228. [Google Scholar] [CrossRef] [PubMed]
- Nelms, K.; Keegan, A.D.; Zamorano, J.; Ryan, J.J.; Paul, W.E. The IL-4 receptor: Signaling mechanisms and biologic functions. Annu. Rev. Immunol. 1999, 17, 701–738. [Google Scholar] [CrossRef]
- Hong, J.; Leung, E.; Fraser, A.G.; Merriman, T.R.; Vishnu, P.; Krissansen, G.W. IL4, IL10, IL16, and TNF polymorphisms in New Zealand Caucasian Crohn’s disease patients. Int. J. Colorectal Dis. 2008, 23, 335–337. [Google Scholar] [CrossRef]
- Durães, C.; Machado, J.C.; Portela, F.; Rodrigues, S.; Lago, P.; Cravo, M.; Ministro, P.; Marques, M.; Cremers, I.; Freitas, J.; et al. Phenotype-genotype profiles in Crohn’s disease predicted by genetic markers in autophagy-related genes (GOIA study II). Inflamm. Bowel Dis. 2013, 19, 230–239. [Google Scholar] [CrossRef]
- Ferguson, L.R.; Han, D.Y.; Huebner, C.; Petermann, I.; Demmers, P.; McCulloch, A.; Gearry, R.B.; Barclay, M.L.; Philpott, M. Single Nucleotide Polymorphisms in IL4, OCTN1 and OCTN2 Genes in Association with Inflammatory Bowel Disease Phenotypes in a Caucasian Population in Canterbury, New Zealand. Open. Gastroenterol. J. 2008, 2, 50–56. [Google Scholar] [CrossRef]
- Connelly, T.M.; Koltun, W.A.; Sangster, W.; Berg, A.S.; Hegarty, J.P.; Harris, L.; Deiling, S.; Stewart, D.B. An interleukin-4 polymorphism is associated with susceptibility to Clostridium difficile infection in patients with inflammatory bowel disease: Results of a retrospective cohort study. Surgery 2014, 156, 769–774. [Google Scholar] [CrossRef]
- Peng, Z.; Hu, P.; Cui, Y.; Li, C. Interleukin (IL)-1beta, IL-1 receptor antagonist and IL-4 gene polymorphisms in ulcerative colitis in the Chinese. Zhonghua Nei Ke Za Zhi 2002, 41, 248–251. [Google Scholar]
- Aithal, G.P.; Day, C.P.; Leathart, J.; Daly, A.K.; Hudson, M. Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn’s disease in a British population. Genes. Immun. 2001, 2, 44–47. [Google Scholar] [CrossRef]
- Onnie, C.; Fisher, S.A.; King, K.; Mirza, M.; Roberts, R.; Forbes, A.; Sanderson, J.; Lewis, C.M.; Mathew, C.G. Sequence variation, linkage disequilibrium and association with Crohn’s disease on chromosome 5q31. Genes. Immun. 2006, 7, 359–365. [Google Scholar] [CrossRef]
- Ebrahimi Daryani, N.; Saghazadeh, A.; Moossavi, S.; Sadr, M.; Shahkarami, S.; Soltani, S.; Farhadi, E.; Rezaei, N. Interleukin-4 and Interleukin-10 Gene Polymorphisms in Patients with Inflammatory Bowel Disease. Immunol. Invest. 2017, 46, 714–729. [Google Scholar] [CrossRef] [PubMed]
- Klein, W.; Tromm, A.; Griga, T.; Fricke, H.; Folwaczny, C.; Hocke, M.; Eitner, K.; Marx, M.; Duerig, N.; Epplen, J.T. Interleukin-4 and interleukin-4 receptor gene polymorphisms in inflammatory bowel diseases. Genes. Immun. 2001, 2, 287–289. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Chen, R.; Tang, S.; Lv, X.; Wu, S.; Zhang, Y.; Yang, Z.; **a, Y.; Chen, D.; Zhan, S. Interleukin-4 and interleukin-10 polymorphisms and antituberculosis drug-induced hepatotoxicity in Chinese population. J. Clin. Pharm. Ther. 2015, 40, 186–191. [Google Scholar] [CrossRef] [PubMed]
- Al-Naseri, M.A.; Salman, E.D.; Ad’hiah, A.H. Association between interleukin-4 and interleukin-10 single nucleotide polymorphisms and multiple sclerosis among Iraqi patients. Neurol. Sci. 2019, 40, 2383–2389. [Google Scholar] [CrossRef] [PubMed]
IBD Group (n = 160) | Control Group (n = 160) | p-Value | |
---|---|---|---|
Gender (%) | |||
Male | 56.3% | 65.0% | p = 0.10 |
Female | 43.7% | 35.0% | |
Age (Mean ± SD) | 32.29 ± 11.85 | 37.73 ± 13.75 | p < 0.001 |
Crohn’s Disease (CD) | Ulcerative Colitis (UC) | |
---|---|---|
Patients N (%) | 86 (53.75%) | 74 (46.25%) |
Gender (%) Male Female | 53.5% 46.5% | 59.5% 40.5% |
Age (Mean ± SD) | 36 ± 9.60 | 34.50 ± 13.72 |
Disease extension (Montreal classification) | L1: 35 | E1: 6 |
L2: 20 | E2: 40 | |
L3: 30 | E3: 28 | |
Disease behavior (for CD) | B1: 39 | N/A |
B2: 28 | N/A | |
B3: 19 | N/A | |
AntiTNF treatment (Y/N) | 64/22 | 28/46 |
Response to antiTNF treatment (Y/N) | 47/17 | 18/10 |
Adverse effects of antiTNF treatment N (%) | 10 (15.6%) | 1 (3.57%) |
Presence of extraintestinal manifestations N (%) * | 21 (24.7%) | 15 (20.27%) |
Colectomy (for UC) N (%) | N/A | 5 (6.75%) |
SNP | Controls (N = 160) | CD (N = 86) | Statistics | UC (N = 74) | Statistics | IBD (N = 160) | Statistics |
---|---|---|---|---|---|---|---|
rs2243250 Minor allele | |||||||
T | 56 (17.5%) | 18 (10.4%) | OR = 0.55 95%CI 0.31–0.97 p = 0.03 | 17 (11.5%) | OR = 0.61 95%CI 0.34–1.09 p = 0.09 | 35 (11%) | OR = 0.57 95%CI 0.36–0.91 p = 0.01 |
Genotype | |||||||
CT + TT | 50 + 3 (33%) | 18 + 0 (21%) | OR = 0.53 95%CI 0.28–0.98 p = 0.04 | 13 + 2 (20.3%) | OR = 0.51 | 31 + 2 (20.6%) | OR = 0.52 95%CI 0.31–0.86 p = 0.01 |
CC | 107 (67%) | 68 (79%) | 59 (79.7%) | 95%CI 0.26–0.98 p = 0.04 | 127 (79.4%) | ||
rs2070874 Minor allele | |||||||
T | 55 (17.2%) | 17 (9.8%) | OR = 0.52 95%CI 0.29–0.94 p = 0.02 | 16 (10.8%) | OR = 0.58 95%CI 0.32–1.55 p = 0.07 | 33 (10.3%) | OR = 0.55 95%CI 0.34–0.88 p = 0.01 |
Genotype | |||||||
CT + TT | 47 + 4 (32%) | 17 + 0 (19.8%) | OR = 0.52 95%CI 0.28–0.98 p = 0.04 | 12 + 2 (19%) | OR = 0.49 95%CI 0.25–0.97 | 29 + 2 (19.4%) | OR = 0.51 95%CI 0.30–0.85 p = 0.01 |
CC | 109 (68%) | 69 (80.2%) | 60 (81%) | p = 0.03 | 129 (80.6%) |
Haplotype rs2243250/rs2070874 | Controls (N = 160) | UC (N = 74) | p | CD (N = 86) | p | IBD (N = 160) | p |
---|---|---|---|---|---|---|---|
CC | 80.94% | 88.51% | 0.04 | 89.53% | 0.01 | 89.06% | 0.003 |
TT | 15.62% | 10.81% | 0.16 | 9.8% | 0.07 | 10.31% | 0.04 |
IL-4 rs2243250 | IL-4 rs2070874 | |||||
---|---|---|---|---|---|---|
p | OR | 95%CI | p | OR | 95%CI | |
CD location | ||||||
Ileal | 0.06 | 0.44 | 0.18–1.07 | 0.07 | 0.45 | 0.18–1.09 |
Colonic | 0.2 | 0.52 | 0.17–1.53 | 0.2 | 0.53 | 0.18–1.56 |
Ileo-colonic | 0.4 | 0.72 | 0.32–1.61 | 0.2 | 0.63 | 0.27–1.47 |
UC location | ||||||
E1 | 0.7 | 0.42 | 0.05–3.38 | 0.2 | 0.19 | 0.01–3.28 |
E2 | 0.1 | 0.59 | 0.28–1.26 | 0.1 | 0.61 | 0.28–1.29 |
E3 | 0.3 | 0.67 | 0.29–1.56 | 0.3 | 0.68 | 0.29–1.60 |
SNP | Patients without EIM (N = 122) | Patients with EIM (N = 36) | Statistics |
---|---|---|---|
rs2243250 | |||
Minor allele | |||
T | 22 (9%) | 13 (18.05 %) | OR = 2.22 95%CI 1.05–4.67 p = 0.03 |
Genotype | |||
CT + TT | 18 + 2 (16.4%) | 13 + 0 (36%) | OR = 2.88 95%CI 1.25–6.62 p = 0.01 |
CC | 102 (83.6%) | 23 (64%) | |
rs2070874 | |||
Minor allele | |||
T | 20 (8.2 %) | 13 (18.05 %) | OR = 2.46 95%CI 1.16–5.25 p = 0.01 |
Genotype | |||
CT + TT | 16 + 2 (14.75%) | 13 + 0 (36%) | OR = 3.26 95%CI 1.40–7.59 p = 0.004 |
CC | 104 (85.25%) | 23 (64%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ionescu, E.M.; Olteanu, A.O.; Tieranu, C.G.; Popa, L.O.; Andrei, S.I.; Preda, C.M.; Dutescu, M.I.; Bo**ca, M.; Tieranu, I.; Popa, O.M. Interleukin-4 Gene Polymorphisms in Romanian Patients with Inflammatory Bowel Diseases: Association with Disease Risk and Clinical Features. Diagnostics 2023, 13, 1465. https://doi.org/10.3390/diagnostics13081465
Ionescu EM, Olteanu AO, Tieranu CG, Popa LO, Andrei SI, Preda CM, Dutescu MI, Bo**ca M, Tieranu I, Popa OM. Interleukin-4 Gene Polymorphisms in Romanian Patients with Inflammatory Bowel Diseases: Association with Disease Risk and Clinical Features. Diagnostics. 2023; 13(8):1465. https://doi.org/10.3390/diagnostics13081465
Chicago/Turabian StyleIonescu, Elena Mirela, Andrei Ovidiu Olteanu, Cristian George Tieranu, Luis Ovidiu Popa, Silvia Ioana Andrei, Carmen Monica Preda, Monica Irina Dutescu, Mihai Bo**ca, Ioana Tieranu, and Olivia Mihaela Popa. 2023. "Interleukin-4 Gene Polymorphisms in Romanian Patients with Inflammatory Bowel Diseases: Association with Disease Risk and Clinical Features" Diagnostics 13, no. 8: 1465. https://doi.org/10.3390/diagnostics13081465